This assay is a simple method to quantitate hematopoietic cells in developing embryonic zebrafish. Blood cells from dissociated zebrafish are subjected to flow cytometry analysis. This allows the detection of blood defects in mutant animals and after genetic modification.
The diversity of cell lineages that comprise mature blood in vertebrate animals arise from the differentiation of hematopoietic stem and progenitor cells (HSPCs). This is a critical process that occurs throughout the lifespan of organisms, and disruption of the molecular pathways involved during embryogenesis can have catastrophic long-term consequences. For a multitude of reasons, zebrafish (Danio rerio) has become a model organism to study hematopoiesis. Zebrafish embryos develop externally, and by 7 days postfertilization (dpf) have produced most of the subtypes of definitive blood cells that will persist for their lifetime. Assays to assess the number of hematopoietic cells have been developed, mainly utilizing specific histological stains, in situ hybridization techniques, and microscopy of transgenic animals that utilize blood cell-specific promoters driving the expression of fluorescent proteins. However, most staining assays and in situ hybridization techniques do not accurately quantitate the number of blood cells present; only large differences in cell numbers are easily visualized. Utilizing transgenic animals and analyzing individuals with fluorescent or confocal microscopy can be performed, but the quantitation of these assays relies on either counting manually or utilizing expensive imaging software, both of which can make errors. Development of additional methods to assess blood cell numbers would be economical, faster, and could even be automated to quickly assess the effect of CRISPR-mediated genetic modification, morpholino-mediated transcript reduction, and the effect of drug compounds that affect hematopoiesis on a large scale. This novel assay to quantitate blood cells is performed by dissociating whole zebrafish embryos and analyzing the amount of fluorescently labelled blood cells present. These assays should allow elucidation of molecular pathways responsible for blood cell generation, expansion, and regulation during embryogenesis, which will allow researchers to further discover novel factors altered during blood diseases, as well as pathways essential during the evolution of vertebrate hematopoiesis.
Blood production (hematopoiesis) is an essential developmental process that first starts in the early embryo. This process begins by generating primitive red blood cells and macrophages directly from mesoderm, and later shifts towards the production of hematopoietic stem and progenitor cells (HSPCs). These stem cells, which are multipotent, generate all of the varieties of mature blood cells in the organism. Capable of self-renewal, the system is continually replenished through these HSPCs. While this process starts early in development, hematopoiesis continues for the life of the animal, providing the ability to transport oxygen to distant sites of the body, to stop bleeding after injury, and to protect the body from infection. The development of this complex system is controlled temporally and spatially during development and any perturbations in blood cell production can be catastrophic for the organism, resulting in anemia, thrombocytopenia, leukopenia, and leukemia.
A popular animal model used for hematopoietic research is the zebrafish (Danio rerio) because they have similar blood development when compared to humans. In fact, many of the genes and molecular pathways used during hematopoiesis are conserved throughout vertebrate evolution, allowing us to learn about human genes by studying zebrafish. Importantly, zebrafish embryos develop outside the body and within 7 days have generated most mature blood cell types, allowing for direct visualization of the hematopoietic system in a short amount of time. Zebrafish are also extremely fecund, which allows researchers to observe a larger number of samples in a short time frame, which is also important for generating reproducible data. The zebrafish's short generation time and external development provides for easier manipulation and observation during mutagenesis studies1,2,3,4,5 and drug screening6,7,8,9,10. This allows a panel of promising therapeutic compounds for human blood disorders to be quickly and efficiently tested.
Importantly, zebrafish are also genetically amenable, and the genome is sequenced and annotated. This tractability allows reverse genetics techniques such as morpholino- (MO-) mediated knockdown and CRISPR-mediated genetic ablation to be performed. Zebrafish have also proven their utility as a model to perform forward genetic screens; many essential genes and pathways involved in vertebrate blood formation have been discovered in this manner. Numerous methods of observing blood cells have also been developed in zebrafish. While traditional histological staining techniques exist, it is also possible to perform in situ hybridization for blood-specific transcripts. Importantly, numerous transgenic lines of fish also exist whereby fluorescent proteins are expressed by lineage-specific promoters, allowing the labelling of specific blood cells with fluorescent proteins11. This allows researchers to perform up-to-the-minute observation of blood cell genesis, expansion, and regulation in a living organism over time.
Overall, conservation of the hematopoietic system, the presence and easy development of transgenic lines, easy visualization, and short generation time has made the zebrafish an economical, fast, and adaptable model of hematopoiesis. To improve upon the toolbox of techniques available for zebrafish researchers, we developed this assay to robustly quantitate the number of blood cells in embryos. The method involves digesting transgenic animals and performing flow cytometry for fluorescent blood cells. In this way, blood cells from mutant animals, the effect of MO and CRISPR modification, and the effect of small molecules can be quantitatively analyzed in a quick and reproducible manner. These assays are user-friendly and economical ways to enumerate blood cells, allowing examination of their generation, proliferation, and maintenance over time.
The Institutional Animal Care and Use Committee (IACUC) advisory board at California State University, Chico, approved all methods described below.
NOTE: It is advised to treat embryos with 1-phenyl 2-thiourea (PTU; Table 1) at 24 hours postfertilization (hpf) to prevent pigmentation which negatively affects fluorescence discrimination by flow cytometry. All procedures listed below are acceptable for flow cytometry and fluorescence-activated cell sorting (FACS). However, if one's goal is to culture the hematopoietic cells after FACS, then adhere to sterile practices when processing samples. The protocol for bleaching and preparing embryo samples in a sterile manner has been described previously12.
1. Dechorionation of 48 hpf zebrafish embryos
2. Preparation of embryo samples for dissociation
3. Embryo dissociation
4. Preparation of dissociated embryos for flow cytometry
5. Flow cytometry
To enumerate red blood cells in embryonic zebrafish, lcr:GFP16 embryos were injected at the one-cell-stage with PBS, 7.0 ng/nL ism1 MO, or 7.0 ng/nL ism1 MO with 7.0 ng ism1 mRNA12. At 48 hpf they were digested and subjected to flow cytometry analysis. After analyzing the percentage of GFP+ red blood cells from each sample (each sample is 5 randomly selected embryos; Figure 1A), the average of all the control group was calculated. This average was set as 1, and all percentages were calculated from that reference point. These data indicate that reducing ism1 transcript with a specific MO reduced the number of GFP+ red blood cells present in the 48 hpf embryo. Additionally, rescuing this reduction in ism1 levels with exogenous mRNA returned the number of red blood cells to normal.
Figure 1: ism1 MO reduces the number of red blood cells produced during embryogenesis. (A) lcr:GFP16 embryos were injected with PBS and subjected to flow cytometry analysis. First, size and granularity were determined, and a gate was drawn around the cell population of interest (cells, left panel). Then, FSC H and FSC W was evaluated to eliminate cells stuck together (singlets FSC). SSC H and W was also evaluated to reduce the possibility of evaluating cells stuck together (singlets SSC). Red fluorescence was then examined to determine live cells (live cells). Finally, live cells were examined for GFP fluorescence (right panel). (B) lcr:GFP12 embryos were injected with PBS (control, circles), ism1 MO (ism1 MO, squares), or ism1 MO + ism1 mRNA12 (rescue, triangles) at the one-cell-stage of development. After 48 h, they were collected, digested, and subjected to flow cytometry as shown in panel A. Each point represents five randomly chosen individual embryos. Fold change is calculated by taking the average percentage of GFP+ cells of the control sample and setting that as 1. All other samples are compared to that average. *p < 0.005, and N.S. = not significant. Please click here to view a larger version of this figure.
Solution | Ingredients | Notes |
E3 medium (50x) | 14.61 g of NaCl, 0.63 g of KCI, 1.99 g of MgSO4·7H2O, 1.83 g of CaCl2·2H2O | To a 2 L graduated cylinder, add the ingredients and enough distilled water to bring the total volume to 1 L. |
E3 medium (1x) | 40 mL of 50x E3 | To a 2 L graduated cylinder, add enough distilled water to bring the total volume to 2 L. |
1-Phenyl-2-thiourea (PTU) in E3 medium | 40 mL of 50x E3 in a 2 L bottle, 40 mg of PTU | To a 2 L graduated cylinder, add enough distilled water to bring the total volume to 2 L. Stir for at least 2 days to completely dissolve PTU. |
Table 1: Recipes for solutions.
Supplemental Figure 1: Digestion of embryos with dissociation protease. Images of 10 embryos not properly digested (left; undigested), after adequate digestion (middle; digested), and after excess digestion (right; overdigested). Please click here to download this figure.
Supplemental Figure 2: Evaluation of two fluorophores in 5 dpf embryos. Gates were drawn to evaluateFSC and SSC to determine the cell population of interest (cells, left column), to evaluate singlets (not shown), to determine live cells (live, middle column), and fluorophore expression (mpx:GFP17 and gata1:DsRed15). First, gates were set on an animal that has no fluorophores (top row). Then mpx:GFP+ (with no gata1:DsRed) animals were evaluated to set the gates and compensation for GFP (second row). gata1:DsRed+ (with no mpx:GFP) animals were evaluated to set the gates and compensation for DsRed (third row). Finally, the two colors can be evaluated in double positive animals that are mpx:GFP+ and gata1:DsRed+. Please click here to download this figure.
Zebrafish are an excellent model system for studying primitive and definitive vertebrate hematopoiesis. Over the past few decades, multiple assays have been developed and refined, allowing zebrafish to become a quick and economical model for testing drugs, generating and testing genetic mutants, and overall allowing researchers to analyze molecular pathways essential for hematopoiesis. This protocol utilizes embryonic zebrafish which allows quick data collection, the use of less physical space than adult animals, and the use of less drugs for large-scale chemical screens. It also allows quantitation after overexpression of mRNA, generation of CRISPR mutants, and MO-induced transcript reduction to alter specific genetic pathways that occur during early embryonic development. Importantly, it allows sensitive, robust quantitation of blood cells, which is difficult to do with in situ hybridization or histological staining techniques.
This assay is flexible and can be modified to answer many research questions. One modification of this protocol can be performed whereby the developmental stage of the animal is manipulated to quantitate different blood cell types. For example, red blood cells arise early in zebrafish development, and with transgenic animals such as the lcr:GFP16 transgenic line can be detected as early as the 16-somite stage. If one is interested in studying thrombocytes, however, the itga2b:GFP18 (also known as cd41:GFP) transgenic line starts expressing GFP at 48 hpf, with mature circulating thrombocytes observed at 72 hpf. If one desires to quantitate B cells with this assay then it can be performed with ighm:EGFP19 transgenic animals closer to 20 dpf. Importantly, this assay can also be used to follow blood cells over time. For example, by analyzing the numbers of lcr:GFP+ cells at 24 hpf, 48 hpf, 72 hpf, one could determine if a genetic modification (or drug) is regulating the maintenance of red blood cells versus just their generation.
These assays allow researchers to reduce gene expression with CRISPR or MOs or overexpress gene expression by injecting mRNA at the one-cell-stage of development and accurately compare the number of blood cells produced in these modified embryos. Care should always be taken to perform proper controls for these experiments at the same time by injecting sibling animals with non-specific guide RNAs or mismatched MOs and examining their blood alongside the experimental groups. The developmental stage is critical; alterations of only a few hours during development could show vastly different numbers of blood cells present in an embryo. In other words, make sure to carefully monitor the hours of development when comparing embryos. To ensure that embryos are age-matched, morphological cues should be utilized. In early embryos, consider counting somites to age-match. Later in development, other markers such as the beginning of the heart beating, the size of the otic vesicle, or length of the body can be used to match the stages of modified fish to control fish. Furthermore, the numbers of total cells can be enumerated from digested embryos to ensure the same number of cells are present in experimental and control animals. In addition to using these assays to examine genetic modification, these assays can also be modified to perform large scale drug screens. Embryos can be exposed to different concentrations of compounds temporally during development to see if the chemicals in question have any effect on hematopoiesis. If the experiment is designed to test the effect of a particular drug, then animals treated with vehicle only should also be included as a control. In these ways, researchers can determine if gain- or loss-of-function of specific genes or signaling pathways play an essential role in hematopoiesis.
It is essential that when examining different transgenes that the number of animals digested per sample is optimized; too few animals may generate little or no fluorescence. This is especially true when examining HSPCs which are not abundant at a particular timepoint. It is also critical when examining transgenics that have weak promoters driving fluorescence. To counteract these issues more animals (and hence, more cells) are required for accurate counts. When altering developmental stages, it is also critical to optimize the digestion time. This protocol is optimized for 5 individual 48 hpf embryos per tube. Digesting more mature embryos will likely require longer time.
Some potential problems can arise during the procedure. If there is no fluorescence observed, there could be a technical issue with the cytometer that needs to be resolved. For this reason, it is essential to verify that the embryos are fluorescent before beginning the procedure by quickly checking them under a microscope. Another common issue is over-digesting the embryos, which destroys the cells. Take care at the digestion step and alter the timing if too many dead cells are observed.
These assays have a few limitations. The largest issue is that these assays are relying on the expression of a transgenic marker. Potentially the change of the transgenic marker's expression may not reflect the biology of what is occurring in the embryo. Additionally, flow cytometry may not be the best method to quantitate cells if the target cell population is extremely low. To deal with these possibilities, other assays such as in situ or histological staining techniques could be utilized. If specific antibodies exist for the cell type of interest immunohistochemistry can also be performed. Embryos could also be subjected to qRT-PCR to measure lineage specific genes, and if these assays are performed on a FACS machine, the cells could be isolated and studied individually with even more sensitive methods. Excluding these issues, this quantitative flow cytometry assay can generate a lot of useful information for researchers.
With these assays, researchers can easily observe hematopoietic defects in vertebrate animals. Modifying genetic pathways with MOs or CRISPR and then performing flow cytometry to elucidate if the gene plays a role in hematopoiesis can be done quickly and is quantitative. Additionally, forward genetic screens (as long as the animals have a fluorescent tag) can be performed and defects assessed. Zebrafish have also become an excellent model for large scale drug screens6,7,8,9,10, allowing efficient drug screening assays on living organisms to observe if the drugs are efficacious and if they have negative effects on development/survival. Coupling this assay with automated flow cytometry technology enhanced by robotics would make it even more efficient20,21,22, allowing truly large-scale analysis and screening of pathways important in blood cell genesis, growth, and regulation that remain obscure.
The authors have nothing to disclose.
Funding was provided by the National Institutes of Health (NIH: R15 DK114732-01 to D.L.S.), the National Science Foundation (NSF: MRI 1626406 to D.L.S.), and from the Honor's Program at California State University Chico (to K.F.R.). The authors thank Betsey Tamietti for laboratory management and Kathy Johns for administrative assistance.
1.5 ml MCF tube | FisherBrand | 05-408-129 | |
10 mm Polystyrene easygrip Petri dish | Corning Falcon | 351008 | |
5 ml Polystyrene round bottom tube with cell strainer cap | Corning Falcon | 352235 | |
BD FACSAria Fusion flow cytometer | BD Biosciences | ||
Dithiolthreitol (DTT) | Sigma-Aldrich | 646563 | |
DPBS (10x) with Ca2+ and Mg2+ | Life Technologies | 14080-055 | |
FBS 500 mL | Gemini Bio-Products | 100-108 | |
HyClone PBS (1x) | GE Healthcare Life Sciences | sh30256.01 | |
Librease | Roche Sigma-Aldrich | 5401119001 | dissociation protease |
Pronase | Roche Sigma-Aldrich | 11459643001 | dechorionation protease |
SYTOX Red Dead Cell Stain | Invitrogen | S34859 |